a story lives forever
Register
Sign in
Form submission failed!

Stay signed in

Recover your password?
Register
Form submission failed!

Web of Stories Ltd would like to keep you informed about our products and services.

Please tick here if you would like us to keep you informed about our products and services.

I have read and accepted the Terms & Conditions.

Please note: Your email and any private information provided at registration will not be passed on to other individuals or organisations without your specific approval.

Video URL

You must be registered to use this feature. Sign in or register.

NEXT STORY

The future of drug research (Part 2)

RELATED STORIES

The future of drug research (Part 1)
James Black Scientist
Comments (0) Please sign in or register to add comments

Well, now I've been trying draw out a model for you of accidentally to deliberately, starting from a native messenger molecule, modifying its chemistry and making compounds which would interfere with the message. I believe that's the general principle. And the way to do it is you start off, and you systematically modify the messenger molecule, and you work your way through. Now, this is slow and tedious. It takes years. So, as much as anything, what you require in this drug research is... is a matter of character. Have you got the bacon, or whatever it is, to keep going? So you... as you know, in these projects we've... in the case of H2, for example, we kept going for years not getting anywhere, and so you have to have this belief that it's doable to keep you going. But when you get there... this is now my belief; my reading of the literature is that molecules which are made as derived from a natural one have got more selectivity than ones which... so what has happened in... since I left big pharma is there have been a number of massive technological revolutions; this was the genome... genomic one, and then the second one was the ability to make combinatorial chemistry, to make molecules at high speed, and then the technology of being able to make a molecule interact in an in vitro system, such that you could screen... well, nowadays they screen 1000's of molecules a day. Now, just to put that in perspective, industry is screening, any one company, 1000 molecules a day. In... since 1988 my group here have made about under 4000 molecules, and of the 4000, we've taken three drugs into man. It so happens none of them have made the grade but, nevertheless, this was... that's what we got out of 4000 compounds. The industry now is doing more than that molecules in a week and yet their productivity in terms of output is dropping, and everybody's worried about it. So this is the question whether the method which is now being discredited because it was too slow – the iterative feedback measurement that the industry used to use – had something going for it which high throughput screenings through just molecules which are in databases – very lumpy databases I have to admit. So I... I think there's something to be learned from it, and I personally think the industry should... it has become obsessed with technology, and we originally were, as I've told my stories, obsessed with physiology. We were trying to deal with heart beta acid secretion and whatnot, and not just us; everybody was doing it for blood pressure, all kinds of things.

The late Scottish pharmacologist Sir James W Black (1924-2010) revolutionised medical treatment of hypertension and angina with his invention of propranolol, the first ever beta blocker. This and his synthesis of cimetidine, used for the treatment of peptic ulcers, earned him the Nobel Prize in Physiology or Medicine in 1988.

Listeners: William Duncan

After graduating with a BSc Bill Duncan went on to gain a PhD from Edinburgh University in 1956. He joined the Pharmaceuticals Division of ICI where he contributed to the development of a number of drugs. In 1958, he started a collaboration with Jim Black working on beta blockers and left ICI with him in 1963 to join the Research Institute of Smith Kline & French as Head of Biochemistry. He collaborated closely with Black on the H2 antagonist programme and this work continued when, in 1968, Duncan was appointed the Director of the Research Institute. In 1979, he moved back to ICI as Deputy Chairman (Technical), a post he occupied until 1986 when he became Chairman and CEO of Coopers Animal Health. He ‘retired’ in 1989 but his retirement was short-lived and he held a number of directorships in venture capital backed companies. One of his part-time activities was membership of the Bioscience Advisory Board of Johnson and Johnson who asked him to become Chairman of the Pharmaceutical Research Institute of Johnson and Johnson in New Jersey. For personal reasons he returned to the UK in 1999, but was retained by Johnson and Johnson until 2006 in a number of senior position in R&D working from the UK. From 1999 to 2007 he was a non-executive director of the James Black Foundation. He is now fully retired.

Tags: 1988

Duration: 3 minutes, 50 seconds

Date story recorded: August 2006

Date story went live: 02 June 2008